Gastrointestinal Cancers: Clinical Trials

8 trials for Gastrointestinal Cancers, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 completed, 1 unknown. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Recruiting 4, Completed 3, Unknown 1
Phase 11Recruiting 1

Follow Gastrointestinal Cancers: new trials by email Literature Review of Gastrointestinal Cancers trials Research Report on Gastrointestinal Cancers

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
BHB810 - Gastric Cancer, Gastric Adenocarcinoma
Phase 1 / Phase 2RecruitingBigHat Biosciences, Inc.1642026-07-162026-10-20
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
Rina-S - Gastrointestinal Cancers
Phase 2RecruitingGenmab1602026-05-112026-11-03
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
18F-FDG, [18F]F-PDL1-3 - Lung Cancer (NSCLC), Cervical Squamous Cell Cancer
Phase 2RecruitingPeking University Cancer Hospital & Institute502026-02-012026-09-29
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
CYTALUXâ„¢ (pafolacianine) injection preoperatively - Esophageal Cancer, Gastrointestinal Cancers
Phase 2RecruitingJohn Waters502025-08-192026-06-05
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
[18F]FAPI-74 PET/CT - Gastrointestinal Cancers, Cholangiocarcinoma
Phase 2CompletedSOFIE1122023-04-282026-10-01
DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients
5-Fluoro-Uracil - Gastrointestinal Cancers
Phase 2CompletedJan Gerard Maring802020-02-022025-01-17
Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Bevacizumab, Placebo - Malignant Ascites, Gastrointestinal Cancers
Phase 2CompletedAIO-Studien-gGmbH532010-02-012015-04-13
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0 - Ovarian Cancer, Peritoneal Cancer
Phase 2UnknownBay Area Gynecology Oncology2002006-09-012019-04-16

Narrower conditions

Gastrointestinal Neoplasms (8)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cholangiocarcinoma (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)  ·  Mesothelioma (1)  ·  Neoplasms (1)

Broader conditions

Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Gastrointestinal Diseases (8)  ·  Neoplasms by Site (8)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Carcinoma (2)  ·  Colonic Diseases (2)  ·  Endocrine Gland Neoplasms (2)  ·  Endocrine System Diseases (2)  ·  Intestinal Diseases (2)  ·  Intestinal Neoplasms (2)  ·  Stomach Diseases (2)  ·  Adenocarcinoma (1)

Interventions

Bevacizumab (1)  ·  Fluorodeoxyglucose F18 (1)  ·  Hyperthermic Intraperitoneal Chemotherapy (1)  ·  Pafolacianine (1)

Sponsors

AIO-Studien-gGmbH (1)  ·  Bay Area Gynecology Oncology (1)  ·  BigHat Biosciences, Inc. (1)  ·  Genmab (1)  ·  Jan Gerard Maring (1)  ·  John Waters (1)  ·  Peking University Cancer Hospital & Institute (1)  ·  SOFIE (1)

Countries

United States (5)  ·  Germany (2)  ·  Netherlands (2)  ·  Australia (1)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Japan (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Hua Zhu (1)  ·  James Lilja, MD (1)  ·  John Waters, M.D. (1)  ·  Karin Jordan, Dr. med. (1)

NIH funding

2025 (1)